Agenus Inc. (AGEN)
| Bid | 3 |
| Market Cap | 77.07M |
| Revenue (ttm) | 103.46M |
| Net Income (ttm) | -227.21M |
| EPS (ttm) | -10.59 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | -1.07 |
| Analyst | Hold |
| Ask | 3.16 |
| Volume | 608,606 |
| Avg. Volume (20D) | 555,695 |
| Open | 3.19 |
| Previous Close | 3.14 |
| Day's Range | 2.90 - 3.17 |
| 52-Week Range | 1.38 - 19.69 |
| Beta | 1.57 |
About AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The...
Analyst Forecast
According to 4 analyst ratings, the average rating for AGEN stock is "Hold." The 12-month stock price forecast is $3, which is a decrease of -1.48% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
20 hours ago · businesswire.com
Agenus to Provide Corporate Update and First Quarter 2025 Financial ReportLEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first...
1 month ago · businesswire.com
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Mee...
